HCG Q2FY25: Revenue increases 14% to Rs 5535 million; PAT surges 33%

Healthcare Global Enterprises announced the financial results for the second quarter of the financial year 2025.

Revenue increased 14 percent to Rs 5535 million in Q2FY25 against Rs 4870 million in Q2FY24.

Profit after tax increased 33 percent to Rs 180 million in Q2FY25 compared to Rs 136 million in Q2FY24.

Adjusted EBITDA stood at Rs 1042 million in Q2FY25, a 21 percent increase from Rs 864 million in Q2FY24.

H1 results highlights
Revenue increased 14 percent to Rs 10791 million in H1FY25 against Rs 9477 million in H1FY24.

Profit after tax increased 42 percent to Rs 301 million in H1FY25 compared to Rs 212 million in H1FY24.

Adjusted EBITDA stood at Rs 1970 million in H1FY25, a 21 percent increase from Rs 1629 million in Q2FY24.

“I am proud to announce strong financial and operational performance for the quarter ended September 2024, a true reflection of the dedication and expertise of our exceptional team, from doctors to support staff, who work tirelessly to provide high-quality care. Having decades of experience, we understand that cancer is a complex disease requiring a unique and focused approach to diagnosis and treatment. Our model centers on patient-centric, personalized care, ensuring that each patient receives treatment precisely tailored to their specific cancer type and stage of progression, and our outcomes are comparable to the best in the Western world. With our network of hospitals spread across the country, we aim to provide this level of treatment to every patient battling cancer,” said Dr B.S. Ajaikumar, Executive Chairman, of HealthCare Global Enterprises Ltd.

“As we look to the future, HCG remains committed to pushing the boundaries of cancer treatment through the integration of advanced technologies and patient-centric innovations. With initiatives like Virtual OPD and centralized genomics, we aim to make high-quality cancer care more accessible and precise, empowering patients with cutting-edge diagnostics and treatment plans tailored to their unique needs. Our journey is made possible by the trust our stakeholders place in us, and we remain dedicated to advancing value-based cancer care across our growing network.”
MB Bureau